Rheumatoid Arthritis
In a world where telemedicine and virtual care are not going away, is there value in patients assessing their own tender and swollen joints?
Work from the Canadian Early Arthritis Cohort (CATCH, @earlyarthritis) presented by Dr. Vivian Bykerk (@BykerkVivian) is the subject of two abstracts from Monday’s poster floor, exploring the utility as to how patient assessments might match up to rheumatologist assessments.
Aurelie Najm AurelieRheumo
3 years 11 months ago
Ultrasound in CSA patients:
Retro US cohort 110pts
28.2% w/ 💥Power Doppler synovitis. 36.8% at 6mo evolved to RA among which 100% PD+ vs 25% PD-
PD + predicts evolution to clinical RA (OR 13.1; CI 1.07-161.04)
Easier and less invasive than MRI!
#Abstr1525 #ACR21 @RheumNow https://t.co/MkhWTvnv3L
Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With multiple JAK inhibitors available in the United States (tofacitinib, baricitinib, and upadacitinib), patients who fail one treatment option have the ability to switch to another agent or change to biologic therapy.
Eric Dein ericdeinmd
3 years 11 months ago
#ACR21 Abs#0819. RheumTAP real-world cohort of pts tapering Rx in remission on RA
▶️ Pts tapering 7.6x ⬆️ likely to flare in f/u
Great convo soon on @Rheumnow re: tapering studies. @davidliew asks how many more times do we need to see drug w/d fail?
https://t.co/BiZSM7yp7o https://t.co/iDXGVpFZzB
Akhil Sood MD AkhilSoodMD
3 years 11 months ago
Abst 0789
Baker & colleagues examined adipokine levels in association with disease activity in RA patients
- Patients with high levels of adipokines less likely to achieve low disease activity & remission
- These patients more likely to escalate to b/tsDMARDs
#ACR21 @RheumNow https://t.co/1xlO4W9q9v
Akhil Sood MD AkhilSoodMD
3 years 11 months ago
Another exciting day at #ACR21 and covering for @RheumNow
Also presented my poster (Abstr 0587) DMARD Use in Medicare Patients with #RheumatoidArthritis and Risk of Long-Term Opioid Use
- DMARD users showed lower odds of long term opioid use compared to non-DMARD users https://t.co/2XZgYY8ORg
David Liew drdavidliew
3 years 11 months ago
We know we're all not as great at treat-to-target in RA as we should be.
If we want to get fit, we join a group class.
If we want to study, we join a study group.
Why not the same with TTT, to motivate us to our best?
Virtual learning collaboratives 👏
#ACR21 ABST0815 @RheumNow https://t.co/siVOyKjPNx
TheDaoIndex KDAO2011
3 years 11 months ago
Dr. R Thomas note that even if you have RA, it's not too late to improve your lifestyle to be healthier. This will help with the mgment of the dz. 2/2 @rheumnow #ACR21
Dr. John Cush RheumNow
3 years 11 months ago
MRI Imaging in RA and SpA: Dr. Sheila Reyes (@RHEUMarampa )
Dr. Sheila Reyes discusses abstracts #0468 and #0469, presented at the #ACR21 annual meeting.
https://t.co/KUoO88dEhQ https://t.co/10R4jC5p0y
Rheum Cat rheum_cat
3 years 11 months ago
Ethnic disparities in pts with RA & CVD - paucity of evidence in published lit
Need to improve study inclusion, diversity to improve quality of care
#ACR21 https://t.co/sWKcHugU9W
The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.
Poster Hall